Health Score

0 Good

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 185 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact185 DOIs

Add abstracts to 7 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact7 DOIs

Deposit reference lists for 6 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact6 DOIs

DOIs for this ISSN

Showing the top 5 of 184 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Resistance to Novel Antiandrogen Therapies in Metastatic Cas… (10.4137/cmo.s34534)	Abstract References ORCID License	104.14	10
2	Targeting Bone Metastases in Metastatic Castration-Resistant… (10.4137/cmo.s30751)	Abstract References ORCID License	77.82	5
3	Cancer-Associated Thrombosis: An Overview (10.4137/cmo.s18991)	ORCID	55.57	166
4	Difference between Luminal A and Luminal B Subtypes Accordin… (10.4137/cmo.s18006)	ORCID	52.51	125
5	Emerging Trends in Hepatocellular Carcinoma: Focus on Diagno… (10.4137/cmo.s9926)	ORCID	50.43	103
6	Bevacizumab for the Treatment of Recurrent Glioblastoma (10.4137/cmo.s7232)	ORCID	48.98	90
7	Galectin-3 as a Potential Target to Prevent Cancer Metastasi… (10.4137/cmo.s29462)	ORCID	48.86	89
8	Cachexia Index in Advanced Non-Small-Cell Lung Cancer Patien… (10.4137/cmo.s30891)	ORCID	48.86	89
9	Classical and Novel Prognostic Markers for Breast Cancer and… (10.4137/cmo.s4773)	ORCID	48.49	86
10	Axitinib: A Review of its Safety and Efficacy in the Treatme… (10.4137/cmo.s10594)	ORCID	47.71	80
11	Obesity Correlation with Metastases Development and Response… (10.4137/cmo.s32812)	ORCID	46.73	73
12	Bevacizumab for the Treatment of Glioblastoma (10.4137/cmo.s8503)	ORCID	45.49	65
13	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Can… (10.4137/cmo.s34540)	ORCID	43.51	54
14	Cytoplasmic Overexpression of HER2: A Key Factor in Colorect… (10.4137/cmo.s10811)	ORCID	43.31	53
15	Mechanisms behind the Resistance to Trastuzumab in HER2-Ampl… (10.4137/cmo.s34537)	ORCID	42.25	48
16	Spinal Osteosarcoma (10.4137/cmo.s10099)	ORCID	41.80	46
17	Glioblastoma Stem Cells as a New Therapeutic Target for Glio… (10.4137/cmo.s30271)	ORCID	41.57	45
18	Clinical Management of Pain in Advanced Lung Cancer (10.4137/cmo.s8360)	ORCID	41.57	45
19	Comparing the Metal Concentration in the Hair of Cancer Pati… (10.4137/cmo.s13410)	ORCID	41.33	44
20	Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clin… (10.4137/cmo.s6460)	ORCID	41.33	44
21	Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvan… (10.4137/cmo.s32821)	ORCID	40.58	41
22	The Importance of Multidisciplinary Approach in Early Detect… (10.4137/cmo.s15239)	ORCID	40.32	40
23	Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pa… (10.4137/cmo.s32813)	ORCID	40.05	39
24	Small Cell Lung Cancer Doubling Time and its Effect on Clini… (10.4137/cmo.s9633)	ORCID	39.78	38
25	Gemcitabine: Efficacy in the Treatment of Advanced Stage Non… (10.4137/cmo.s6252)	ORCID	39.49	37
26	Big Data for Cancer Research (10.4137/cmo.s38279)	Abstract ORCID	38.91	5
27	Novel Treatments for Metastatic Cutaneous Melanoma and the M… (10.4137/cmo.s5855)	ORCID	38.91	35
28	Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsir… (10.4137/cmo.s4482)	ORCID	38.60	34
29	Influenza Vaccination in Cancer Patients Undergoing Systemic… (10.4137/cmo.s13774)	ORCID	38.29	33
30	Review of the Treatment of Non-Small Cell Lung Cancer with G… (10.4137/cmo.s7340)	ORCID	38.29	33
31	Transgenic and Knockout Mice Models to Reveal the Functions… (10.4137/cmo.s7516)	ORCID	38.29	33
32	The Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in… (10.4137/cmo.s15476)	ORCID	37.63	31
33	Treatment-Induced Bone Loss and Fractures in Cancer Patients… (10.4137/cmo.s8511)	ORCID	37.28	30
34	A Six-Year Study of the Clinical Presentation of Cervical Ca… (10.4137/cmo.s12017)	ORCID	36.56	28
35	Opioid-Induced Constipation in Advanced Illness: Safety and… (10.4137/cmo.s4867)	ORCID	36.56	28
36	Is Adherence to Imatinib Mesylate Treatment among Patients w… (10.4137/cmo.s32822)	ORCID	36.18	27
37	Melatonin, a Promising Role in Taxane-Related Neuropathy (10.4137/cmo.s4132)	ORCID	36.18	27
38	Vandetanib for the Treatment of Metastatic Medullary Thyroid… (10.4137/cmo.s7999)	ORCID	36.18	27
39	Expression of Concern for “Exvivo Experiments of Human Ovari… (10.4137/cmo.s11911)	Abstract References ORCID	35.78	2
40	Nelarabine in the Treatment of Refractory T-Cell Malignancie… (10.4137/cmo.s4364)	ORCID	35.78	26
41	Safety and Efficacy of Vinorelbine in the Treatment of Non-S… (10.4137/cmo.s5074)	ORCID	35.78	26
42	Inhibitors of Glioma Growth that Reveal the Tumour to the Im… (10.4137/cmo.s7685)	ORCID	35.78	26
43	Acute Myeloid Leukemia: Focus on novel Therapeutic Strategie… (10.4137/cmo.s7244)	ORCID	35.37	25
44	Ad-REIC Gene Therapy: Promising Results in a Patient with Me… (10.4137/cmo.s23252)	ORCID	34.95	24
45	Survival of Patients with Squamous Cell Malignancies of the… (10.4137/cmo.s8103)	ORCID	34.95	24
46	Advanced Extramammary Paget's Disease of the Groin, Penis, a… (10.4137/cmo.s13107)	ORCID	34.51	23
47	Monitoring Metastasis and Cachexia in a Patient with Breast… (10.4137/cmo.s40479)	ORCID	34.51	23
48	Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Ca… (10.4137/cmo.s6197)	ORCID	34.51	23
49	Aflibercept in the Treatment of Metastatic Colorectal Cancer (10.4137/cmo.s7432)	ORCID	34.51	23
50	Current and Emerging Pharmacotherapies for Primary CNS Lymph… (10.4137/cmo.s7752)	ORCID	34.51	23